@Article{096504017X15139039328978,
AUTHOR = {Yuping Shen, Chunyan Li, Weixing Liu, Wei Mao, Hong Qian, Hui Wang, Qing Xu},
TITLE = {Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients},
JOURNAL = {Oncology Research},
VOLUME = {26},
YEAR = {2018},
NUMBER = {5},
PAGES = {801--807},
URL = {http://www.techscience.com/or/v26n5/56693},
ISSN = {1555-3906},
ABSTRACT = {This study investigated the characteristics of oxaliplatin-induced hypersensitivity reactions (HSRs) and evaluated the efficacy of premedication for controlling HSRs among colorectal cancer patients. A retrospective study 
was performed on the clinical records of 291 patients with colorectal cancer in The Tenth People’s Hospital of 
Shanghai from January 2008 to January 2016. Patients who experienced HSRs to oxaliplatin were compared 
with those who did not. A total of 291 colorectal cancer patients received oxaliplatin, with 39 (13.40%) experiencing HSRs. Oxaliplatin-free interval and premedication with dexamethasone and antihistamine were independent variables for oxaliplatin-related HSRs. Rechallenging patients with premedication was successful in 72.2% 
of the patients who successfully completed their treatment. Attention should be paid to patients with any prior 
exposure to oxaliplatin. Patients with grades 1 and 2 HSRs can successfully rechallenge with oxaliplatin and 
complete their treatment by premedication with dexamethasone and antihistamine.},
DOI = {10.3727/096504017X15139039328978}
}